Attila MekisThierry PinguetGianlorenzo MasiniSubal SahniMichael MackSteffen GloecknerPeter De DobbelaereSpringer Berlin HeidelbergPinguet T, Armijo G, Balardeta J et al. Advanced silicon photonic transceivers. Proceed- ings of Group IV Photonics. 2015:21-22...
This is achieved by harnessing the T-cell compartment of the immune system. It is this strategy and its translation to a clinical trial that is the subject of the current application. 1.2. TetMYB vaccine Human MYB cDNA (containing three inactivating mutations in its reading frame) will be ...
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors Invest New Drugs, 34 (5) (2016), pp. 604-613 CrossrefView in ScopusGoogle Scholar 34 A.E.D. Van Swearingen, M.J. Sambade, M.B. Siegel, et al....
(2015) 112, 650–659 | doi: 10.1038/bjc.2014.653 Keywords: HSP90 inhibitors; molecular chaperone; phase I study A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies A Spreafico1, J-P Delord2, L De ...
and especially in first-line settings, clinical outcomes can be improved, even with regimens that exclude chemotherapy. These observations support our prior reports that combinations of targeted agents, such as matched CDK4/6 inhibitors and MEK inhibitors (given when cognate pathway co-alterations such...
Conclusion: Our study supports further clinical evaluation of CDK4/6i and their combination with anti-BRAF/MEK therapies as a novel effective treatment against advanced thyroid tumors. Moreover, the complementary use of our 11 genes predictor with p16/KI67 evaluation could...
Blumenschein Jr G, Smit EF, Planchard D, Kim DW, Cadranel J, De Pas T, et al. A randomized phase 2 study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non- small cell lung cancer (NSCLC). Ann Oncol. 2015;26(5):894-901....
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.doi:10.1038/S41416-018-0355-8Vincent A. de WegerMaja de JongeMarlies H. G. LangenbergJan H. M. Schellens...
Blumenschein GR, Smit EF, Planchard D, Kim DW, Cadranel J, De Pas T, et al. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small- cell lung cancer (NSCLC). Ann Oncol. 2015;26(5):894-901....
303 A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumors - European Journal of Cancerdoi:10.1016/S0959-8049(16)30169-1V. De WegerA. VargaM. De JongeM. Langenberg...